J. Miguel

发表

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

Juliane C. Dohm, A. Valencia, R. Guigó, 2011, Nature.

Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy

Rajesh Chopra, Bruno Paiva, J. Miguel, 2014, Molecular Cancer Therapeutics.

Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia

J. Miguel, J. García, N. Gutiérrez, 2005, Leukemia.

Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.

E. Raineri, S. Heath, R. Siebert, 2015, Genome research.

A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

M. Beksac, K. Anderson, M. Dimopoulos, 2019, Journal of Clinical Oncology.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Hans Erik Johnsen, Giampaolo Merlini, Robert A Kyle, 2014, The Lancet. Oncology.

Multiple myeloma: differential diagnosis and prognosis

J. Miguel, R. García-Sanz, 2004 .

Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers

Paul Flicek, Simon Heath, Angelika Merkel, 2015, Genome research.

A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone).

A. Jakubowiak, J. Miguel, W. Crist, 2015 .

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Kenneth C. Anderson, Benjamin Djulbegovic, Bart Barlogie, 2003, British journal of haematology.

International uniform response criteria for multiple myeloma

M. Beksac, B. Barlogie, K. Anderson, 2006, Leukemia.

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

B. Barlogie, K. Anderson, G. Morgan, 2008, Leukemia.

Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study

J. Martinez-Climent, M. Piris, J. Miguel, 2003, Leukemia.

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility

J. Miguel, A. Oriol, L. Corchete, 2018, Haematologica.

Thalidomide alone or in combination: results in refractory patients

J. Miguel, 2009 .

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

R. Vij, J. Miguel, M. Tomasson, 2013, Leukemia.

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

G. Morgan, A. Jakubowiak, A. Krishnan, 2020, Leukemia.

Both CD133+ Cells and Monocytes Provide Significant Improvement for Hindlimb Ischemia, Although They do not Transdifferentiate Into Endothelial Cells

J. Miguel, F. Sánchez-Guijo, S. Muntión, 2010, Cell transplantation.

Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients

J. Miguel, A. Órfão, J. Hernández, 1995, British journal of haematology.

Bone marrow histopathologic patterns and immunologic phenotype in B-cell chronic lymphocytic leukaemia

Marcos González, J. Miguel, A. Órfão, 1988, Blut: Zeitschrift für die Gesamte Blutforschung.

Current challenges in the management of patients with relapsed/refractory multiple myeloma.

J. Miguel, M. Mateos, 2011, Oncology.

PLASMA CELL LEUKEMIA : Consensus Statement on Diagnostic Requirements , Response Criteria , and Treatment Recommendations by the International Myeloma Working Group ( IMWG )

Saad, Pieter, K. Anderson, 2014 .

Evaluation of prognostic factors among patients with chronic graft-versus-host disease

J. Miguel, J. Pérez-Simón, M. Remberger, 2012, Haematologica.

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde

H. Goldschmidt, M. Dimopoulos, H. Einsele, 2021, Haematologica.

Diagnosis and Staging of Multiple Myeloma and Related Disorders

R. Fonseca, J. Miguel, S. Rajkumar, 2018 .

In the future, more intensive therapeutic approaches should be planned for asymptomatic high-risk patients to prevent definitively the development of myeloma-related symptomatology. Practice Points Asymptomatic (smoldering) myeloma: treatment strategy MANAGEMENT PERSPECTIVE

J. Miguel, M. Mateos, 2013 .

Asymptomatic (smoldering) myeloma: treatment strategy

J. Miguel, M. Mateos, 2013 .

Target Expression , Genera tion , Preclinical Activity , and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM 801 for Multiple Myeloma Treatment Graphical

C. Klein, D. Hose, F. Prósper, 2022 .

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

J. Miguel, N. Puig, I. Melero, 2015, Leukemia.

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

H. Goldschmidt, M. Dimopoulos, J. Miguel, 2016, Haematologica.

International Myeloma Working Group recommendations for global myeloma care

M. Dimopoulos, A. Palumbo, J. Miguel, 2014, Leukemia.

TCRαβ+/CD4+ Large Granular Lymphocytosis: A New Clonal T-Cell Lymphoproliferative Disorder

Ana Helena Santos, Marcos González, J. Miguel, 2003 .

Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell‐related disorders

J. Miguel, M. Pérez‐Andrés, A. Órfão, 2010, Cytometry. Part B, Clinical cytometry.

Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma

K. Anderson, F. Prósper, J. Miguel, 2015 .

Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes

J. Miguel, J. Rivas, J. García, 2005, Leukemia.

Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response.

J. Miguel, Jesús M. Hernández, N. Gutiérrez, 2009, Leukemia research.

FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.

Marcos González, J. Miguel, R. García-Sanz, 2004, The hematology journal : the official journal of the European Haematology Association.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2013, The Lancet. Oncology.

M. Dimopoulos, A. Palumbo, P. Sonneveld, 2015, Haematologica.

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

H. Goldschmidt, H. Einsele, P. Sonneveld, 2021, Blood Cancer Journal.

Induction therapy for newly diagnosed multiple myeloma.

S. Lonial, J. Miguel, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

LEADING ARTICLE International uniform response criteria for multiple myeloma

M. Beksac, B. Barlogie, G. Morgan, 2006 .

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

J. Miguel, A. Oriol, J. Besalduch, 2012, Haematologica.

Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

J. Miguel, S. Brunet, J. Pérez-Simón, 2003, Blood.

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

J. Miguel, A. Oriol, N. Gutiérrez, 2010, The Lancet. Oncology.

and decreases the production of Th1 cytokines Bortezomib induces selective depletion of alloreactive T lymphocytes

J. Miguel, A. Pandiella, B. Blanco, 2012 .

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

E. Campo, P. Flicek, F. Prósper, 2019, bioRxiv.

vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study

M. Terol, J. Miguel, J. Sierra, 2002 .

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

L. Escoda, J. Miguel, N. Gutiérrez, 2007, Leukemia.

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma

H. Goldschmidt, J. Miguel, N. Kröger, 2006, Bone Marrow Transplantation.

Myeloma: Update on supportive care strategies

J. Miguel, R. García-Sanz, 2003, Current treatment options in oncology.

Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial

M. Terol, J. Miguel, A. Oriol, 2008 .

Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.

H. Einsele, J. Miguel, G. Jackson, 2005, Cancer treatment reviews.

Waldenström’s Macroglobulinemia Immunophenotype

J. Miguel, N. Puig, E. Ocio, 2017 .

Correction/Maintenance Dosing (Front Loading) of Darbepoetin alfa: Final Results from a Randomized Phase 3 Active Controlled Trial.

Lisa Anne Hendricks, J. Miguel, J. Canon, 2004 .

CD34+ Cells from Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Normal Bone Marrow Display Different Apoptosis and Drug Resistance–Associated Phenotypes

M. Tormo, J. Miguel, A. Órfão, 2004, Clinical Cancer Research.

Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR

J. Miguel, M. Alonso, D. Gonzalez, 2003, Leukemia.

Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma

J. Miguel, J. Bladé, J. Lahuerta, 2000, British journal of haematology.

The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen

F. Prósper, J. Garcia-conde, J. Miguel, 2002, Transfusion.

Heterogeneity of structural abnormalities in the 7q31.3∼q34 region in myeloid malignancies

F. Solé, J. Hernández, J. Miguel, 2004 .

Detection of minimal residual disease in myeloid malignancies

Marcos González, J. Miguel, A. Órfão, 2004 .

Richter transformation driven by Epstein–Barr virus reactivation during therapy‐related immunosuppression in chronic lymphocytic leukaemia

Antonio Martínez, J. Martinez-Climent, F. Prósper, 2018, The Journal of pathology.

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

J. Miguel, X. Agirre, A. Oriol, 2018, Haematologica.

The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival

F. Prósper, Marcos González, J. Miguel, 2016 .

Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment

J. Miguel, 2014 .

Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation

J. Miguel, A. Órfão, P. Menéndez, 2004, Leukemia.

lymphoproliferative disorders with more than one B-cell clone Incidence and clinicobiologic characteristics of leukemic B-cell chronic

Marcos González, J. Miguel, Jesús M. Hernández, 2011 .

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

J. Miguel, N. Munshi, D. Reece, 2015 .

Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities

J. Miguel, A. Hagemeijer, A. Órfão, 2003, Leukemia.

Immunophenotypic Analysis of the TCR-Vβ Repertoire in 98 Persistent Expansions of CD3+/TCR-αβ+ Large Granular Lymphocytes: Utility in Assessing Clonality and Insights into the Pathogenesis of the Disease

Ana Helena Santos, Marcos González, J. Miguel, 2001 .

Running title: The cellular origin and pathogenesis of WM

J. Miguel, A. Órfão, N. Puig, 2015 .

New Criteria To Identify Risk of Progression in Monoclonal Gammopathy of Uncertain Significance: Multiparametric Flow Cytometry Analysis of Bone Marrow Plasma Cells.

J. Miguel, A. Órfão, M. Vidriales, 2006 .

Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)â/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadeâ as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial.

M. Terol, J. Miguel, A. Oriol, 2009 .

followed by maintenance myeloma patients receiving short induction with weekly bortezomib Outcome according to cytogenetic abnormalities and DNA ploidy in

J. Miguel, A. Oriol, N. Gutiérrez, 2012 .

Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment

F. Prósper, J. Miguel, A. Oriol, 2010 .

Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy

M. Dimopoulos, A. Palumbo, J. Miguel, 2017 .

Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)

M. Dimopoulos, J. Miguel, J. H. Lee, 2017 .

of the International Myeloma Workshop Consensus Panel 3 Consensus recommendations for standard investigative workup: report

S. Jagannath, J. Miguel, N. Munshi, 2012 .

Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM)

B. Barlogie, G. Morgan, A. Palumbo, 2011 .

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.

A. Krishnan, S. Lonial, J. Miguel, 2022, The Lancet. Haematology.

A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

D. Siegel, J. Miguel, M. Dolled-Filhart, 2014 .

T‐cell subpopulations in patients with monoclonal gammopathies: Essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia

J. Miguel, M. González, M. Caballero, 1985, American journal of hematology.

A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib

J. Miguel, A. Oriol, J. Bladé, 2010 .

Clarification of the definition of complete response in multiple myeloma

J. Miguel, B. Durie, J. Bladé, 2015, Leukemia.

detection in multiple myeloma Prognostic value of deep sequencing method for minimal residual disease

Marcos González, J. Miguel, N. Puig, 2014 .

Expression of lymphoid‐associated antigens in mast cells: report of a case of systemic mast cell disease

J. Miguel, A. Órfão, J. Villarrubia, 1995, British journal of haematology.

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

H. Goldschmidt, M. Dimopoulos, H. Einsele, 2019, Haematologica.

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving graft versus host disease prophylaxis with tacrolimus plus methotrexate or sirolimus

J. Miguel, J. González-Porras, F. Sánchez-Guijo, 2016 .

Hematologic Profiles in the Phase 3 APEX Trial.

H. Goldschmidt, P. Sonneveld, S. Lonial, 2005 .

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

M. Dimopoulos, H. Einsele, A. Palumbo, 2016, Drugs.

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

F. Prósper, J. Miguel, A. Oriol, 2016, The Lancet. Oncology.

Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria.

H. Goldschmidt, G. Morgan, M. Dimopoulos, 2019, Journal of Clinical Oncology.

Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial

J. Miguel, A. Oriol, B. Paiva, 2017 .

Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial

J. Miguel, A. Órfão, N. Puig, 2017 .

Lymphoid subsets and prognostic factors in multiple myeloma

J. Miguel, A. Órfão, M. Sanz, 1992, British journal of haematology.

report of the International Myeloma Workshop Consensus Panel 2 Consensus recommendations for risk stratification in multiple myeloma

J. Shaughnessy, M. Dimopoulos, A. Palumbo, 2011 .

Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals

J. Miguel, J. Rivas, P. Maiso, 2007, Leukemia.

Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics

J. Miguel, A. Órfão, N. Gutiérrez, 2005, Leukemia.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

J. Miguel, C. Bokemeyer, N. Kröger, 2008, Leukemia.

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials

D. Esseltine, J. Miguel, A. Oriol, 2016, Annals of Hematology.

Management of treatment-emergent peripheral neuropathy in multiple myeloma

P. Wen, G. Morgan, M. Dimopoulos, 2012, Leukemia.

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

Marcos González, J. Miguel, A. Órfão, 1997 .

Human Bone Marrow Stromal Cells Differentiate into Corneal Tissue and Prevent Ocular Graft-Versus-Host Disease in Mice

J. Miguel, S. Carrancio, C. Herrero, 2015, Cell transplantation.

A New Staging System for Multiple Myeloma Based on the Number of S-Phase Plasma Cells

Marcos González, J. Miguel, R. García-Sanz, 1995 .

Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia

J. Miguel, H. Dombret, C. Chastang, 1998 .

International uniform response criteria for multiple myeloma

B. Barlogie, G. Morgan, M. Dimopoulos, 2006, Leukemia.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project

B. Barlogie, G. Morgan, J. Miguel, 2018, Blood Cancer Journal.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

H. Goldschmidt, G. Morgan, A. Palumbo, 2012, Leukemia.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

H. Goldschmidt, G. Morgan, A. Palumbo, 2012, Leukemia.

Symposium 30: Molecular diagnosis of lymphoma

G. Morgan, J. Miguel, E. Macintyre, 2002 .

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, The Lancet. Oncology.

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

U. Mellqvist, M. Dimopoulos, H. Einsele, 2016, Leukemia.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

J. San Miguel, J. Miguel, C. Bokemeyer, 2008, Leukemia.

1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma

Pingping Qu, Fadi Towfic, Konstantinos Mavrommatis, 2018 .

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

J. Miguel, A. Pandiella, J. García, 2009, Leukemia.

MyelomA Genetics International Consortium

H. Goldschmidt, G. Morgan, H. Einsele, 2012, Leukemia & lymphoma.

Therapy in Newly Diagnosed Acute Promyelocytic Leukemia Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by

J. Miguel, H. Dombret, A. Stamatoullas, 2014 .

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.

J. Miguel, H. Dombret, A. Stamatoullas, 2000 .

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

J. Miguel, H. Dombret, A. Stamatoullas, 1999, Blood.

myeloma Immunoglobulin gene rearrangements and the pathogenesis of multiple

G. Morgan, Marcos González, J. Miguel, 2013 .

Treatment of High-Risk Acute Lymphoblastic Leukemia. Preliminary Results of the Protocol PETHEMA ALL-93

M. Terol, J. Garcia-conde, J. Miguel, 1998 .

NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

J. Miguel, A. Pandiella, F. Sánchez-Guijo, 2014, Clinical Cancer Research.

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

M Boccadoro, B. Barlogie, G. Morgan, 2009, Leukemia.

Survival and years of life lost in different age cohorts of patients with multiple myeloma.

B. Barlogie, A. Palumbo, P. Sonneveld, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

patients from the International Myeloma Working Group favorable features and shows better survival: an analysis of 10 549 Myeloma in patients younger than age 50 years presents with more

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2008 .

Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study

J. Miguel, N. Puig, A. Oriol, 2015 .

Immunophenotypic Diagnosis of Leukemic B-Cell Chronic Lymphoproliferative Disorders Other Than Chronic Lymphocytic Leukemia

J. Miguel, A. Órfão, J. Almeida, 2004 .

Investigation of Minimal Residual Disease in Acute Myeloid Leukemia by Immunophenotyping

J. Miguel, A. Órfão, M. Vidriales, 2003 .

Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation

J. Miguel, A. Órfão, M. González, 1998, Transfusion.

lymphoproliferative disorders comparison between 2 prospective studies in patients with Nonmyeloablative transplantation with or without alemtuzumab

J. Miguel, C. Craddock, D. Linch, 2013 .

Immunophenotypic Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia

J. Miguel, A. Órfão, M. González, 1997 .

Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse

J. Hernández-Rivas, J. Miguel, L. Corchete, 2016, Oncotarget.

Multifunctional role of Erk 5 in multiple myeloma

J. Miguel, J. Montero, A. Esparís-Ogando, 2005 .

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284)

B. Barlogie, G. Morgan, M. Dimopoulos, 2006 .

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

G. Morgan, M. Dimopoulos, A. Palumbo, 2014, Leukemia.

Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study

H. Goldschmidt, M. Dimopoulos, J. Miguel, 2012 .

Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience

J. Miguel, J. Bourhis, H. Dombret, 2005, Leukemia.

Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment

M. Dimopoulos, D. Siegel, J. Miguel, 2015 .

CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

H. Goldschmidt, M. Dimopoulos, J. Miguel, 2014 .

Overall survival of patients with relapsed and refractory multiple myeloma: adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone

G. Morgan, M. Dimopoulos, A. Palumbo, 2014 .

Lenalidomide: a new therapy for multiple myeloma.

G. Morgan, H. Einsele, P. Sonneveld, 2008, Cancer treatment reviews.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

P. Sonneveld, J. Miguel, M. Boccadoro, 2013, Haematologica.

Novel therapeutic agents for the management of multiple myeloma patients with renal impairment

M. Dimopoulos, S. Jagannath, J. Miguel, 2012 .

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

M. Dimopoulos, J. Miguel, P. Richardson, 2008 .

Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment

J. Miguel, M. Pérez‐Andrés, A. Órfão, 2005, Leukemia.

Haematological cancer: Redefining myeloma

J. Miguel, S. Rajkumar, G. Merlini, 2012, Nature Reviews Clinical Oncology.

is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

J. Miguel, N. Puig, J. Rodríguez, 2020 .

Characterization of aberrant phenotypes in acute myeloblastic leukemia

J. Miguel, A. Órfão, M. González, 1995, Annals of Hematology.

Association between trisomy 8 and the immunophenotype of blast cells from acute leukemias secondary to a myelodysplastic syndrome or chronic myeloproliferative disorders

J. Miguel, A. Órfão, J. García, 1997, Annals of Hematology.

Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

C. E. Pedreira, J. Miguel, M. Schilham, 2020, Modern Pathology.

Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation

J. Miguel, A. Órfão, J. Pérez-Simón, 2006, Leukemia & lymphoma.

PreclinicalActivityoftheOralProteasomeInhibitorMLN9708 in Myeloma Bone Disease

J. Miguel, A. Berger, D. Chauhan, 2014 .

The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.

J. Delgado, J. Miguel, J. Sierra, 2007 .

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

J. Miguel, C. Dumontet, X. Thomas, 2007 .

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.

S. Jagannath, S. Lonial, D. Siegel, 2020 .

Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics

J. Miguel, A. Órfão, J. Pérez-Simón, 1997, Annals of Hematology.

Treatment of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) with Concurrent Chemotherapy and Imatinib Mesylate.

J. Esteve, M. Tormo, Marcos González, 2004 .

Immunological features of sporadic multinodular goiter

J. Miguel, A. Órfão, M. González, 1993, The clinical investigator.

LYMPHOID NEOPLASIA C 1013 G / CXCR 4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma

J. Miguel, A. Roccaro, A. Sacco, 2014 .

The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML

J. Miguel, A. Órfão, M. González, 1994, Annals of Hematology.

Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification

J. Miguel, A. Órfão, E. Ocio, 2014, Leukemia.

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study

J. Miguel, G. Martinelli, A. Belch, 2003, British journal of haematology.

Defining and treating high-risk multiple myeloma

J. Miguel, M. Bhutani, M. Mateos, 2015, Leukemia.

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

D. Esseltine, P. Sonneveld, S. Lonial, 2013 .

melphalan-prednisone versus melphalan-prednisone analysis of the phase 3 VISTA study of bortezomib plus therapy: diagnosed multiple myeloma patients treated with nonintensive Superior outcomes associated with complete response in newly

D. Esseltine, A. Palumbo, J. Miguel, 2012 .

Report of the European Myeloma Network (EMN) workshop on multiparametric flow cytometry in multiple myeloma and related disorders

C. Pellat-deceunynck, P. Sonneveld, H. Johnsen, 2007 .

Reply to A. Gratwohl

H. Einsele, J. Miguel, N. Kröger, 2011 .

Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial

J. Miguel, H. Dombret, A. Vekhoff, 2003, Leukemia.

Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies

H. Goldschmidt, J. Miguel, M. Pfreundschuh, 2013 .

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

J. Miguel, J. González-Porras, J. Hernández, 2004, Leukemia.

Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma

J. Miguel, C. Solano, J. Bargay, 2002, Leukemia & lymphoma.

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

Wei Chen, G. Morgan, M. Dimopoulos, 2009, Leukemia.

Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis).

M. Dimopoulos, J. Miguel, J. Zeldis, 2007 .

ECOG Performance Status Affects Efficacy, but Not Safety, of Lenalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma (MM009/010 Sub-Analysis).

M. Dimopoulos, J. Miguel, A. Chanan-Khan, 2007 .

Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.

M. Dimopoulos, J. Miguel, S. Iida, 2019, Journal of Clinical Oncology.

An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma

J. Fay, J. Miguel, P. Moreau, 2014 .

DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity

E. Álava, J. Miguel, J. Montero, 2008 .

Initial treatment of transplant-ineligible patients in multiple myeloma

A. Palumbo, J. Miguel, X. Leleu, 2014, Expert review of hematology.

Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.

D. Siegel, J. Miguel, N. Munshi, 2016 .

Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.

M. Dimopoulos, H. Einsele, S. Lonial, 2015 .

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

M. Dimopoulos, H. Einsele, S. Lonial, 2014 .

Whole-genome sequencing identifies recurrent mutations in chronic lymphocyticleukaemia

A. Valencia, R. Guigó, X. Estivill, 2011 .

Multiple myeloma: a model for scientific and clinical progress

J. Miguel, 2014 .

Overexpression of the VAV proto‐oncogene product is associated with B‐cell chronic lymphocytic leukaemia displaying loss on 13q

J. Hernández, J. Miguel, X. Bustelo, 2006, British journal of haematology.

Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis

Marcos González, J. Miguel, R. García-Sanz, 2002, British journal of haematology.

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

D. Esseltine, M. Dimopoulos, A. Palumbo, 2008 .

Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial.

J. Miguel, P. Richardson, A. Regnault, 2009 .

A352 Impact of Complete Response on Quality of Life in Newly Diagnosed Multiple Myeloma Patients

J. Miguel, P. Richardson, A. Regnault, 2009 .

Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?

M. Terol, J. Miguel, A. Oriol, 2008 .

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project

B. Barlogie, G. Morgan, J. Miguel, 2018, Blood Cancer Journal.

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

M. Dimopoulos, C. Hofmeister, J. Miguel, 2017 .

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

H. Goldschmidt, M. Dimopoulos, A. Jakubowiak, 2017 .

Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

F. Prósper, J. Miguel, P. Richardson, 2008 .

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

J. Miguel, A. Oriol, J. Bladé, 2012 .

The Activity of Spanish and Italian Myeloma Groups

J. Miguel, M. Boccadoro, A. Larocca, 2009 .

New Alternatives for the Evaluation of Minimal Residual Disease (MRD) Detection By Next Generation Sequencing in Multiple Myeloma

Marcos González, J. Miguel, A. Órfão, 2017 .

Analysis of Immunophenotypic Response (IR) by Multiparameter Flow Cytometry In 516 Myeloma Patients Included In Three Consecutive Spanish Trials

M. Terol, J. Miguel, A. Oriol, 2010 .

Influence of the Intensity of the Conditioning Regimen on the Characteristics of Acute and Chronic Graft Versus Host Disease after Allogeneic Transplantation.

J. Miguel, J. Sierra, S. Brunet, 2004 .

Multiple myeloma gammopathies A high-risk , Double-Hit , group of newly diagnosed myeloma identi fi ed by genomic analysis

H. Goldschmidt, G. Morgan, H. Einsele, 2018 .

Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.

M. Dimopoulos, J. Miguel, P. Richardson, 2008 .

PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY

Michael D. Robbins, M. Dimopoulos, J. Miguel, 2019, HemaSphere.

Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.

J. Miguel, N. Munshi, R. Mogg, 2017 .

Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).

M. Dimopoulos, A. Jakubowiak, D. Siegel, 2016 .

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.

H. Goldschmidt, G. Morgan, P. Sonneveld, 2009 .

Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study

J. Shah, A. Palumbo, S. Jagannath, 2016 .

Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma

D. Hose, F. Prósper, J. Miguel, 2015 .

Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone

M. Dimopoulos, A. Palumbo, J. Miguel, 2008 .

International uniform response criteria for multiple myeloma

B. Barlogie, G. Morgan, M. Dimopoulos, 2007, Leukemia.

Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

M. Dimopoulos, A. Palumbo, S. Lonial, 2015 .

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

D. Esseltine, M. Dimopoulos, A. Palumbo, 2011 .

Methods for Detection of Minimal Residual Disease

J. Miguel, J. Dongen, J. San Miguel, 1997 .

The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685)

S. Lonial, J. Miguel, R. Hájek, 2017 .

LBA28CARFILZOMIB (K) VS LOW-DOSE CORTICOSTEROIDS AND OPTIONAL CYCLOPHOSPHAMIDE (CY) IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 3 STUDY (FOCUS)

M. Dimopoulos, A. Palumbo, J. Miguel, 2014 .

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

M. Dimopoulos, J. Miguel, S. Delorme, 2018, Blood Cancer Journal.

Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)

H. Goldschmidt, M. Dimopoulos, J. Miguel, 2013 .

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial

Á. Payer, J. Miguel, N. Puig, 2015, Haematologica.

PLASMABLASTIC MULTIPLE MYELOMA: AN IMMUNOLOGICALLY DIFFERENT SUBTYPE

J. Miguel, M. González, M. Moro, 1987, British journal of haematology.

Introduction to a series of reviews on multiple myeloma.

J. Miguel, 2015 .

Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model.

J. Miguel, P. Atadja, A. Pandiella, 2007 .

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

J. Miguel, P. Richardson, N. Raje, 2016 .

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

H. Goldschmidt, P. Sonneveld, J. Miguel, 2012 .

Zalypsis Has Synergistic Effect When Combined with Bortezomib + Dexamethasone through Caspase Dependent and Mainly Independent Mechanisms and through A Potent Induction of DNA Damage

E. Álava, J. Miguel, A. Pandiella, 2010 .

Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial

J. Miguel, A. Oriol, N. Gutiérrez, 2013 .

Bortezomib in the Upfront Treatment of Multiple Myeloma

J. Miguel, M. Mateos, 2011 .

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).

M. Dimopoulos, A. Jakubowiak, D. Siegel, 2015 .

Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.

D. Esseltine, P. Ganly, J. Miguel, 2016 .

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

D. Esseltine, M. Dimopoulos, A. Palumbo, 2009 .

Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs)

F. Prósper, J. Miguel, A. Órfão, 2016 .

Genomic Profiles of Bone Marrow (BM) Clonal Plasma Cells (PCs) Vs Circulating Tumor Cells (CTCs) and Extramedullary (EM) Plasmacytomas in Multiple Myeloma (MM)

F. Prósper, R. Valdés-Mas, Diana A. Puente, 2016 .

Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM)

B. Barlogie, G. Morgan, J. Miguel, 2016 .

Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials

J. Miguel, N. Puig, A. Oriol, 2015 .

Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study

J. Miguel, G. Gaidano, R. Hájek, 2017 .

Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation

J. Miguel, J. González-Porras, R. García-Sanz, 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).

A. Krishnan, J. Miguel, J. Goldberg, 2020 .

Long Non-Coding RNAs Annotation and Their Involvement in Multiple Myeloma

F. Prósper, J. Miguel, A. Melnick, 2016 .

1 NADPH oxidases as therapeutic targets in chronic myeloid leukemia

J. Miguel, C. Cañizo, C. Guerrero, 2014 .

Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis

J. Miguel, A. Pandiella, E. Ocio, 2007, Leukemia.

Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma

J. Miguel, J. S. San Miguel, J. Bladé, 2004, British journal of haematology.

International staging system for multiple myeloma.

J. Crowley, B. Barlogie, G. Morgan, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A172 Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau

M. Dimopoulos, A. Palumbo, J. Miguel, 2009 .

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival : an analysis of 10 549 patients from the International Myeloma Working Group

B. Barlogie, M. Dimopoulos, P. Sonneveld, 2008 .

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.

D. Esseltine, M. Dimopoulos, J. Miguel, 2010, Blood.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Alessandro Corso, Robin Foà, M. Dimopoulos, 2007, The New England journal of medicine.

Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes.

J. Miguel, A. Órfão, J. S. San Miguel, 1998, Blood.

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.

K. Anderson, H. Einsele, P. Sonneveld, 2009, Blood.

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

J. Shaughnessy, M. Dimopoulos, P. Sonneveld, 2011, Blood.

Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

Joan, M. Rozman, J. Miguel, 1998, The American journal of pathology.

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.

M. Dimopoulos, P. Sonneveld, J. Miguel, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients

J. Miguel, A. Órfão, J. S. San Miguel, 2004, International journal of cancer.

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

J. Shah, U. Mellqvist, M. Dimopoulos, 2014, Leukemia.

Antimyeloma Action of the Multikinase Inhibitor TG02

J. Miguel, A. Pandiella, E. Ocio, 2010 .

Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM)

H. Goldschmidt, M. Dimopoulos, J. Miguel, 2013 .

Combination of interferon and dexamethasone in refractory multiple myeloma

J. Miguel, J. S. San Miguel, J. Hernández, 1990, Hematological oncology.

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

F. Prósper, J. Miguel, A. Oriol, 2016 .

Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.

M. Dimopoulos, P. Sonneveld, J. Miguel, 2017 .

Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)

F. Prósper, J. Miguel, P. Maiso, 2016 .

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).

M. Dimopoulos, R. Vij, T. Zimmerman, 2016 .

CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

S. Lonial, J. Miguel, P. Richardson, 2017 .

CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

S. Lonial, J. Miguel, P. Richardson, 2017 .

Immunophenotypic approach to the identification and

J. Miguel, M. Pérez‐Andrés, H. Merle-Beral, 2004 .

Cell surface markers in multiple myeloma.

J. Miguel, J. S. San Miguel, G. Ruiz-Argüelles, 1994, Mayo Clinic proceedings.

Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside.

F. Prósper, J. Miguel, N. Munshi, 2007 .

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

J. Miguel, H. Dombret, C. Chastang, 1998, Blood.

Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.

J. Miguel, J. S. San Miguel, M. González, 2009, Oral diseases.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

H. Goldschmidt, A. Palumbo, H. Johnsen, 2014, The Lancet. Oncology.

Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312)

G. Morgan, P. Sonneveld, J. Miguel, 2004 .

Management of treatment-emergent peripheral neuropathy in multiple myeloma

P. Wen, G. Morgan, M. Dimopoulos, 2012, Leukemia.

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group

M. Dimopoulos, J. Miguel, S. Delorme, 2018, Blood Cancer Journal.

A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma

M. Dimopoulos, R. Vij, T. Zimmerman, 2015 .

Long Term Follow-up on the Tretament of High Risk Smoldering Myeloma with Lenalidomide Plus Low Dose Dex (Rd) (phase III spanish trial): Persistent Benefit in Overall Survival

F. Prósper, J. Miguel, A. Oriol, 2014 .

Preliminary Report from an Exploratory Phase II Trial with Plitidepsin (Aplidin®) in Patients with Refractory/Relapsed Multiple Myeloma.

F. Prósper, J. Miguel, P. Richardson, 2005 .

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma

P. Sonneveld, J. Miguel, A. Nagler, 2014 .

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

J. Miguel, X. Agirre, A. Oriol, 2018, Haematologica.

Relapse/Refractory myeloma patient: potential treatment guidelines.

J. Miguel, 2009 .

Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy

J. Miguel, A. Pandiella, E. Ocio, 2014, Molecular Cancer Therapeutics.

Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts

F. Prósper, J. Martín-Subero, J. Miguel, 2021, American journal of hematology.

A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).

P. Sonneveld, C. Hofmeister, D. Siegel, 2016 .

KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).

S. Jagannath, J. Miguel, A. Palumbo, 2016 .

A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.

H. Goldschmidt, S. Lonial, J. Miguel, 2016 .

KEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM).

A. Palumbo, S. Jagannath, J. Miguel, 2016 .

Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma

M. Dimopoulos, D. Siegel, J. Miguel, 2008 .

Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

M. Dimopoulos, S. Lonial, J. Miguel, 2017 .

New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM)

F. Prósper, J. Miguel, P. Maiso, 2016 .